Review



ω agatoxin iva tfa  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress ω agatoxin iva tfa
    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel <t>antagonist</t> <t>ω-agatoxin</t> <t>IVA</t> on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
    ω Agatoxin Iva Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p1080a/%CF%89-Agatoxin+IVA/pm40361281-147-35-50
    Average 93 stars, based on 1 article reviews
    ω agatoxin iva tfa - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance."

    Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.

    Journal: British journal of pharmacology

    doi: 10.1111/bph.70048

    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
    Figure Legend Snippet: FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.

    Techniques Used: Inhibition, Saline, Comparison

    Related Articles

    Inhibition:

    Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.
    Article Snippet: ATP (Cat. No. HY-B2176), retinoic acid (RA, Cat. No. HY-14649), acadesine (Cat. No. HY-13417), dorsomorphin (Cat. No. HY-13418A), coenzyme Q10 (Cat. No. HY-N0111), paclitaxel (Cat. No. HY-B0015), (-)-(S)-BayK8644 (Cat. No. HY-15124), GV-58 (Cat. No. HY-12498), ω-agatoxin IVA TFA (Cat. No. HY-P1080A) and ziconotide acetate (Cat. No. HY-P0062B) were purchased from MedChemExpress (Shanghai, China).

    Saline:

    Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.
    Article Snippet: ATP (Cat. No. HY-B2176), retinoic acid (RA, Cat. No. HY-14649), acadesine (Cat. No. HY-13417), dorsomorphin (Cat. No. HY-13418A), coenzyme Q10 (Cat. No. HY-N0111), paclitaxel (Cat. No. HY-B0015), (-)-(S)-BayK8644 (Cat. No. HY-15124), GV-58 (Cat. No. HY-12498), ω-agatoxin IVA TFA (Cat. No. HY-P1080A) and ziconotide acetate (Cat. No. HY-P0062B) were purchased from MedChemExpress (Shanghai, China).

    Comparison:

    Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.
    Article Snippet: ATP (Cat. No. HY-B2176), retinoic acid (RA, Cat. No. HY-14649), acadesine (Cat. No. HY-13417), dorsomorphin (Cat. No. HY-13418A), coenzyme Q10 (Cat. No. HY-N0111), paclitaxel (Cat. No. HY-B0015), (-)-(S)-BayK8644 (Cat. No. HY-15124), GV-58 (Cat. No. HY-12498), ω-agatoxin IVA TFA (Cat. No. HY-P1080A) and ziconotide acetate (Cat. No. HY-P0062B) were purchased from MedChemExpress (Shanghai, China).



    Similar Products

    ω agatoxin iva tfa  (MedChemExpress)
    93
    MedChemExpress ω agatoxin iva tfa
    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel <t>antagonist</t> <t>ω-agatoxin</t> <t>IVA</t> on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
    ω Agatoxin Iva Tfa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p1080a/%CF%89-Agatoxin+IVA/pm40361281-147-35-50
    Average 93 stars, based on 1 article reviews
    ω agatoxin iva tfa - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ω-agatoxin iva  (MedChemExpress)
    93
    MedChemExpress ω-agatoxin iva
    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel <t>antagonist</t> <t>ω-agatoxin</t> <t>IVA</t> on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
    ω Agatoxin Iva, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p1080a/%CF%89-Agatoxin+IVA/custom%40hy-p1080a%4040361281
    Average 93 stars, based on 1 article reviews
    ω-agatoxin iva - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    p q type vgccs blocker ω agatoxin iva  (MedChemExpress)
    93
    MedChemExpress p q type vgccs blocker ω agatoxin iva
    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel <t>antagonist</t> <t>ω-agatoxin</t> <t>IVA</t> on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.
    P Q Type Vgccs Blocker ω Agatoxin Iva, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p1080a/%CF%89-Agatoxin+IVA/pm40317242-64-5-24
    Average 93 stars, based on 1 article reviews
    p q type vgccs blocker ω agatoxin iva - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.

    Journal: British journal of pharmacology

    Article Title: Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance.

    doi: 10.1111/bph.70048

    Figure Lengend Snippet: FIGURE 9 The effect of N-type and P/Q-type calcium channel inhibition on the development of morphine tolerance. (a, b) Timeline of the experiment. (c) Effect of N-type calcium channel antagonist ziconotide on development of morphine tolerance. Ziconotide exerted an antinociceptive effect, and there was no significant difference in % maximal possible antinociceptive effect (MPE) between rats treated with morphine (10 μg per 5 μl, twice daily) and ziconotide (0.05 μg per 5 μl, once daily) and morphine-tolerant (MT) rats. *P < 0.05 versus normal- saline (NS) rats according to repeated measures (RM) two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group. (d) Effect of P/Q-type calcium channel antagonist ω-agatoxin IVA on development of morphine tolerance. ω-agatoxin IVA (0.05 μg) exerted an antinociceptive effect, and on Day 3, %MPE in rats treated with morphine (10 μg per 5 μl, twice daily) and ω-agatoxin (0.05 μg per 5 μl, once daily) was lower than that in MT rats. *P < 0.05 versus NS rats; #P < 0.05 versus MT rats according to RM two- way ANOVA with Tukey's multiple comparison test. Data are means ± SEM; n = 6 per group.

    Article Snippet: ATP (Cat. No. HY-B2176), retinoic acid (RA, Cat. No. HY-14649), acadesine (Cat. No. HY-13417), dorsomorphin (Cat. No. HY-13418A), coenzyme Q10 (Cat. No. HY-N0111), paclitaxel (Cat. No. HY-B0015), (-)-(S)-BayK8644 (Cat. No. HY-15124), GV-58 (Cat. No. HY-12498), ω-agatoxin IVA TFA (Cat. No. HY-P1080A) and ziconotide acetate (Cat. No. HY-P0062B) were purchased from MedChemExpress (Shanghai, China).

    Techniques: Inhibition, Saline, Comparison